Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249103 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
A Phase 2 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03249103 is a Phase 2 study that has completed, run by Aptinyx. The registered enrollment target is 22 participants.
The verdict
NCT03249103, a Phase 2 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.
Interventions
- DRUG Placebo oral capsule
- DRUG NYX-2925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2019-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03249103
The ClinicalTrials.gov registry entry for NCT03249103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03249103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03249103 about?
NCT03249103 is a clinical study titled "Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia". The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic r...
What is the current status of trial NCT03249103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2017-08-14. Estimated completion is 2019-04-18.
What interventions are being tested in trial NCT03249103?
The interventions under investigation include: Placebo oral capsule (DRUG), NYX-2925 (DRUG).
Who is sponsoring clinical trial NCT03249103?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.